tiprankstipranks
Advertisement
Advertisement

ANAB Stock Latest News

First Tracks Biotherapeutics initiated with an Outperform at Leerink
The FlyFirst Tracks Biotherapeutics initiated with an Outperform at Leerink
4h ago
ANAB
TRAX
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
2d ago
ANAB
AnaptysBio price target lowered to $63 from $79 at Barclays
PremiumThe Fly
AnaptysBio price target lowered to $63 from $79 at Barclays
2d ago
ANAB
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
3d ago
GSK
ANAB
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
PremiumCompany Announcements
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
4d ago
8K
ANAB
AnaptysBio completes separation of First Tracks Biotherapeutics
PremiumThe FlyAnaptysBio completes separation of First Tracks Biotherapeutics
4d ago
ANAB
AnaptysBio price target raised to $95 from $67 at Piper Sandler
Premium
The Fly
AnaptysBio price target raised to $95 from $67 at Piper Sandler
24d ago
ANAB
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
Premium
Ratings
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
25d ago
ANAB
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
PremiumCompany Announcements
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
28d ago
8K
ANAB
AnaptysBio announces $100M share repurchase program
PremiumThe Fly
AnaptysBio announces $100M share repurchase program
28d ago
ANAB
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
PremiumThe Fly
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
28d ago
ANAB
AnaptysBio price target raised to $90 from $70 at UBS
PremiumThe Fly
AnaptysBio price target raised to $90 from $70 at UBS
1M ago
ANAB
AnaptysBio: Buy Rating on Durable Jemperli Royalties and High-Impact TRAX Pipeline Upside
PremiumRatingsAnaptysBio: Buy Rating on Durable Jemperli Royalties and High-Impact TRAX Pipeline Upside
1M ago
ANAB
AnaptysBio price target raised to $50 from $36 at Truist
Premium
The Fly
AnaptysBio price target raised to $50 from $36 at Truist
2M ago
GSK
ANAB
AnaptysBio price target raised to $85 from $56 at Stifel
Premium
The Fly
AnaptysBio price target raised to $85 from $56 at Stifel
2M ago
ANAB
Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted
PremiumCompany Announcements
Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted
2M ago
ANAB
AnaptysBio: Structural Separation and Advancing Autoimmune Pipeline Support Overweight Rating and Value Upside
PremiumRatings
AnaptysBio: Structural Separation and Advancing Autoimmune Pipeline Support Overweight Rating and Value Upside
2M ago
ANAB
AnaptysBio price target raised to $66 from $51 at H.C. Wainwright
PremiumThe Fly
AnaptysBio price target raised to $66 from $51 at H.C. Wainwright
2M ago
ANAB
AnaptysBio price target raised to $79 from $78 at Barclays
PremiumThe Fly
AnaptysBio price target raised to $79 from $78 at Barclays
2M ago
ANAB
AnaptysBio provides update on potential spin-off of biopharma operations
PremiumThe FlyAnaptysBio provides update on potential spin-off of biopharma operations
2M ago
GSK
ANAB
AnaptysBio reports Q4 EPS $1.58, consensus 93c
Premium
The Fly
AnaptysBio reports Q4 EPS $1.58, consensus 93c
2M ago
ANAB
AnaptysBio price target raised to $78 from $55 at Barclays
Premium
The Fly
AnaptysBio price target raised to $78 from $55 at Barclays
3M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >